Exenatide biobetter - Biolingus

Drug Profile

Exenatide biobetter - Biolingus

Alternative Names: Exenatide oral - Biolingus; Exenatide sublingual - Biolingus; Project A1 (OPUS) - Biolingus

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vitapharm Technology Development
  • Developer Biolingus; Vitapharm Technology Development
  • Class Antihyperglycaemics; Biobetters; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 18 Sep 2017 Exanatide biobetter - Biolingus is available for licensing as of 18 Sep 2017. http://www.biolingus.ch/index.html#partners
  • 18 Sep 2017 Discontinued - Phase-I for Type-2 diabetes mellitus in China (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
  • 18 Sep 2017 Preclinical trials in Type-2 diabetes mellitus in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top